ArticleCureus2026
Effect of Probiotics and Therapeutic Additives on the Osmolality of Pasteurized Donor Human Milk.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aims to examine changes in the osmolality of pasteurized donor human milk (PDHM) following the addition of probiotics and commonly used neonatal additives.
methodsThe osmolality of PDHM was measured at 10 minutes using a calibrated osmometer by a technician blinded to the probiotics and additives used in the study. The osmolality of 5 mL of PDHM was measured after the addition of four different probiotics and commonly used additives, including caffeine, cephalexin, domperidone, esomeprazole, fluconazole, furosemide, ibuprofen, lansoprazole, levetiracetam, paracetamol, phenobarbitone, sildenafil, and ursodeoxycholic acid, administered separately in therapeutic doses. The osmolality of the oral iodinated non-ionic contrast agent (Omnipaque) was measured after 1:2 and 1:4 dilution with sterile water. The volume of PDHM required to be added to each additive to keep the osmolality below 450 mOsm/kg, as recommended by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), was calculated.
resultsThe mean osmolality of PDHM was 256 mOsm/kg, which, on reconstitution with most additives, exceeded 450 mOsm/kg. The osmolality of pure additives ranged from 161 to >2000 mOsm/kg. There was a significant increase in the osmolality of PDHM beyond the recommended 450 mOsm/kg with most additives, except caffeine, cephalexin, esomeprazole, fluconazole, furosemide, lansoprazole, and sildenafil. A maximum increase in osmolality to 1723 mOsm/kg (range 260-1723 mOsm/kg) was observed with probiotics. Domperidone, ibuprofen, levetiracetam, paracetamol, phenobarbitone, and ursodeoxycholic acid increased the osmolality beyond 450 mOsm/kg. The osmolality of the iodinated non-ionic contrast agent (Omnipaque), when diluted with sterile water in a 1:4 ratio, was 461 mOsm/kg.
conclusionThe addition of probiotics to PDHM increases osmolality and requires appropriate dilution to maintain levels below the recommended 450 mOsm/kg. Therapeutic additives such as domperidone, ibuprofen, levetiracetam, paracetamol, phenobarbitone, and ursodeoxycholic acid also increase the osmolality of PDHM and require appropriate dilution. Future research should focus on developing probiotics and additives with lower osmolality to improve safety in neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.